An interesting observation from such studies is the distinct over-representation of HER2-positive DCIS compared with IDC, which contrasts the aggressive phenotype that HER2-positive tumors display in invasive disease [19, 20]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.